Background: Nonsteroidal anti-inflammatory drugs (NSAIDS) are among the most common causes of drug hypersensitivity (HS) reactions. The diagnosis is based on a careful clinical history, and provocation tests are considered the gold standard for diagnosis. Skin tests have some value to study reactions to pyrazolones. Laboratory investigations are mostly used for research purposes. Different phenotypes have been described. Objective and Methods: Our aim was to describe the most common clinical manifestations of NSAID HS in a large population of adult patients, the drugs involved, the association with previously described risk factors, and the outcome of diagnostic procedures. The classification of reactions proposed by the European Academy of Allergy and Clinical Immunology (EAACI) Drug Allergy Interest Group was adopted. Results: Acetylsalicylic acid was the drug most often involved in reactions (34%), isolated cutaneous symptoms were the most reported (60%), and immediate reactions (58%) were the most common. There was an overall female predominance (64%) and 35% of the patients were atopic. HS to NSAIDs was confirmed in 21% of the patients. The most common phenotypes encountered among HS patients were NSAID-induced urticaria/angioedema and single-NSAID-induced urticaria/angioedema or anaphylaxis. Logistic regression analysis showed that gender and atopy were not significant risk factors for HS confirmation, but diagnosis depended on the number of previous reactions, the type of reaction, and the time interval between drug intake and reaction. Conclusion: Only 21% of suspected HS reactions were confirmed after diagnostic workup. Patients describing >1 previous reaction and suffering immediate reactions had a higher probability of a positive investigation.

Keywords:
Diagnostic workup, Drug hypersensitivity, Drug provocation tests, Drug allergy, Nonsteroidal anti-inflammatory drugs, Phenotypes, Risk factors, Clinical investigation
1.
Aagaard L, Strandell J, Melskens L, Petersen PS, Holme Hansen E: Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™. Drug Saf 2012;35:1171-1182.
2.
Gomes ER, Demoly P: Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005;5:309-316.
3.
Doña I, Blanca-Lopez N, Torres MJ, Garcia-Campos J, Garcia-Nuñez I, Gómez F, Salas M, Rondon C, Canto MG, Blanca M: Drug hypersensitivity reactions: patterns of responses, drug involved and temporal variation in a large series of patients evaluated. J Investig Allergy Clin Immunol 2012;22:363-371.
4.
Kurt E, Demir AU, Cadirci O, Yildirim H, Pinar Eser T: Immediate-type drug hypersensitivity and associated factors in a general population. Allergol Immunopathol (Madr) 2011;39:27-31.
5.
Blanca-López N, Doña I, Perkins JR, Canto G, Cornejo-García JA, Blanca M: Multiple nonsteroidal anti-inflammatory drug-induced cutaneous disease: relevance, natural evolution and relationship with atopy. Int Arch Allergy Immunol 2014;164:147-148.
6.
Settipane RA, Constantine HP, Settipane GA: Aspirin intolerance and recurrent urticaria in normal adults and children. Epidemiology and review. Allergy 1980;35:149-154.
7.
Erbagci Z: Multiple NSAID intolerance in chronic idiopathic urticaria is correlated with delayed, pronounced and prolonged autoreactivity. J Dermatol 2004;31:376-382.
8.
Jenkins C, Costello J, Hodge L: Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004;328:434.
9.
Kim JE, Kountakis SE: The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery. Ear Nose Throat J 2007;86:396-399.
10.
Karakaya G, Celebioglu E, Kalyoncu AF: Non-steroidal anti-inflammatory drug hypersensitivity in adults and the factors associated with asthma. Respir Med 2013;107:967-974.
11.
Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Cortellini G, Nizankowska-Mogilnicka E, Quaratino D, Romano A, Sanchez-Borges M, Torres-Jaen MJ: Clinical management of patients with a history of urticaria/angioedema induced by multiple NSAIDs: an expert panel review. Int Arch Allergy Immunol 2013;160:126-133.
12.
Quiralte J, Blanco C, Castillo R, Delgado J, Carrillo T: Intolerance to nonsteroidal anti-inflammatory drugs: results of controlled drug challenges in 98 patients. J Allergy Clin Immunol 1996;98:678-685.
13.
Sánchez-Borges M, Capriles-Hulett A: Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity. Ann Allergy Asthma Immunol 2000;84:101-106.
14.
Gomes E, Cardoso MF, Praça F, Gomes L, Mariño E, Demoly P: Self-reported drug allergy in a general adult Portuguese population. Clin Exp Allergy 2004;34:1597-1601.
15.
Rebelo Gomes E, Fonseca J, Araujo L, Demoly P: Drug allergy claims in children: from self-reporting to confirmed diagnosis. Clin Exp Allergy 2008;38:191-198.
16.
Faria E, Rodrigues-Cernadas J, Gaspar A, Botelho C, Castro E, Lopes A, Gomes E, Malheiro D, Cadinha S, Campina-Costa S, Neto M, Sousa N, Rodrigues-Alves R, Romeira A, Caiado J, Morais-Almeida M; Portuguese Society of Allergology and Clinical Immunology; Drug Allergy Interest Group: Drug-induced anaphylaxis survey in Portuguese Allergy Departments. J Investig Allergol Clin Immunol 2014;24:40-48.
17.
Stevenson DD, Sanchez-Borges M, Szczeklik A: Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol 2001;87:177-180.
18.
Quiralte J, Blanco C, Delgado J, Ortega N, Alcntara M, Castillo R, Anguita JL, Sáenz de San Pedro B, Carrillo T: Challenge-based clinical patterns of 223 Spanish patients with nonsteroidal anti-inflammatory-drug-induced-reactions. J Investig Allergol Clin Immunol 2007;17:182-188.
19.
Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, Bousquet P, Celik G, Demoly P, Gomes ER, Niżankowska-Mogilnicka E, Romano A, Sanchez-Borges M, Sanz M, Torres MJ, De Weck A, Szczeklik A, Brockow K: Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy 2011;66:818-829.
20.
Caimmi S, Caimmi D, Bousquet PJ, Demoly P: How can we better classify NSAID hypersensitivity reactions? Validation from a large database. Int Arch Allergy Immunol 2012;159:306-312.
21.
Cavkaytar O, Arik Yilmaz E, Karaatmaca B, Buyuktiryaki B, Sackesen C, Sekerel BE, Soyer O: Different phenotypes of non-steroidal anti-inflammatory drug hypersensitivity during childhood. Int Arch Allergy Immunol 2015;167:211-221.
22.
Kowalski ML, Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Bochenek G, Brockow K, Campo P, Celik G, Cernadas J, Cortellini G, Gomes E, Niżankowska-Mogilnicka E, Romano A, Szczeklik A, Testi S, Torres MJ, Wöhrl S, Makowska J: Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy 2013;68:1219-1232.
23.
Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, Brockow K, Pichler WJ, Demoly P; European Network for Drug Allergy (ENDA); EAACI Drug Allergy Interest Group: Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003;58:854-863.
24.
Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, Swierczynska M, Picado C, Scadding G, Kowalski ML, Setkowicz M, Ring J, Brockow K, Bachert C, Wöhrl S, Dahlén B, Szczeklik A: EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 2007;62:1111-1118.
25.
Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, Brown SG, Camargo CA Jr, Cydulka R, Galli SJ, Gidudu J, Gruchalla RS, Harlor AD Jr, Hepner DL, Lewis LM, Lieberman PL, Metcalfe DD, O'Connor R, Muraro A, Rudman A, Schmitt C, Scherrer D, Simons FE, Thomas S, Wood JP, Decker WW: Second symposium on the definition and management of anaphylaxis: summary report - Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium. J Allergy Clin Immunol 2006;117:391-397.
26.
Muraro A, Roberts G, Clark A, Eigenmann PA, Halken S, Lack G, Moneret-Vautrin A, Niggemann B, Rancé F; EAACI Task Force on Anaphylaxis in Children: The management of anaphylaxis in childhood: position paper of the European Academy of Allergology and Clinical Immunology. Allergy 2007;62:857-871.
27.
Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, Bircher A, Blanca M, Bonadonna B, Campi P, Castro E, Cernadas JR, Chiriac AM, Demoly P, Grosber M, Gooi J, Lombardo C, Mertes PM, Mosbech H, Nasser S, Pagani M, Ring J, Romano A, Scherer K, Schnyder B, Testi S, Torres M, Trautmann A, Terreehorst I: Skin test concentrations for systemically administered drugs - an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013;68:702-712.
28.
Cohen J: The t test for means; in: Analysis for the Behavioral Sciences, ed 2. New Jersey, Lawrence Erlbaum Associates, 1988, pp 19-74.
29.
Blanca-Lopez N, Torres MJ, Doña I, Campo P, Rondón C, Seoane Reula ME, Salas M, Canto G, Blanca M: Value of the clinical history in the diagnosis of urticaria/angioedema induced by NSAIDs with cross-intolerance. Clin Exp Allergy 2013;43:85-91.
30.
Nissen CV, Bindslev-Jensen C, Mortz CG: Hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs): classification of a Danish patient cohort according to EAACI/ENDA guidelines. Clin Transl Allergy 2015;5:10.
31.
Helin-Salmivaara A, Klaukka T, Huupponen R: Heavy users of non-steroidal anti-inflammatory drugs: a nationwide prescription database study in Finland. Eur J Clin Pharmacol 2003;59:477-482.
32.
Rasmussen HM, Søndergaard J, Kampmann JP, Andersen M: General practitioners prefer prescribing indicators based on detailed information on individual patients: a Delphi study. Eur J Clin Pharmacol 2005;61:237-241.
33.
Grimmsmann T, Himmel W: Polypharmacy in primary care practices: an analysis using a large health insurance database. Pharmacoepidemiol Drug Saf 2009;18:1206-1213.
34.
Viola M, Rumi G, Valluzzi RL, Gaeta F, Caruso C, Romano A: Assessing potential determinants of positive provocation tests in subjects with NSAID hypersensitivity. Clin Exp Allergy 2011;41:96-103.
35.
Demir S, Olgac M, Unal D, Gelincik A, Colakoglu B, Buyukozturk S: Evaluation of hypersensitivity reactions to nonsteroidal anti-inflammatory drugs according to the latest classification. Allergy 2015;70:1461-1467.
36.
Couto M, Gaspar A, Piedade S, Arêde C, Menezes M, Sousa MJ, Sousa G, Morais-Almeida M: IgE-mediated metamizole allergy and the usefulness of the cellular allergen stimulation test. Eur Ann Allergy Clin Immunol 2012;44:113-116.
37.
Dursun AB, Woessner KA, Simon RA, Karasoy D, Stevenson DD: Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. Ann Allergy Asthma Immunol 2008;100:420-425.
38.
Rubio M, Bousquet PJ, Gomes E, Romano A, Demoly P: Results of drug hypersensitivity evaluations in a large group of children and adults. Clin Exp Allergy 2012;42:123-130.
39.
Çelik GE, Erkekol FÖ, Aydın Ö, Demirel YS, Mısırlıgil Z: Are drug provocation tests still necessary to test the safety of COX-2 inhibitors in patients with cross-reactive NSAID hypersensitivity? Allergol Immunopathol (Madr) 2013;41:181-188.
40.
Kim YJ, Lim KH, Kim MY, Jo EJ, Lee SY, Lee SE, Yang MS, Song WJ, Kang HR, Park HW, Chang YS, Cho SH, Min KU, Kim SH: Cross-reactivity to acetaminophen and celecoxib according to the type of nonsteroidal anti-inflammatory drug hypersensitivity. Allergy Asthma Immunol Res 2014;6:156-162.
41.
Dona I, Blanca-Lopez N, Cornejo-Garcia JA, Torres MJ, Laguna JJ, Fernandez J, Rosado A, Rondón C, Campo P, Agúndez JA, Blanca M, Canto G: Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clin Exp Allergy 2011;41:86-95.
42.
Ayuso P, Blanca-López N, Doña I, Torres MJ, Guéant-Rodríguez RM, Canto G, Sanak M, Mayorga C, Guéant JL, Blanca M, Cornejo-García JA: Advanced phenotyping in hypersensitivity drug reactions to NSAIDs. Clin Exp Allergy 2013;43:1097-1109.
43.
Çelik G, Mungan D, Ozer F, Ediger D, Bavbek S, Sin B, Demirel YS, Mısırlıgil Z: Clinical features and atopy profile in Turkish subjects with analgesic intolerance. J Asthma 2002;39:101-106.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.